Governor Mike Braun has announced a significant investment by RayzeBio, Inc., a company under Bristol Myers Squibb, aimed at expanding its operations in Indiana. This expansion reinforces Indiana’s status as the Radiopharmaceutical Capital of the World.
Major Investment in Life Sciences
RayzeBio plans to invest over $173 million to enhance its radiopharmaceutical manufacturing capabilities in Indiana. This includes the establishment of a new facility in Whitestown alongside its existing operations in Indianapolis. The initiative is expected to generate up to 100 high-paying jobs by 2029, contributing to the state’s growing life sciences sector.
Commitment to Job Creation
Governor Braun emphasized the state’s unprecedented investment in the life sciences industry, with a commitment of $1 billion over the next decade to create 100,000 new jobs. He stated, “RayzeBio’s expansion and planned job creation will contribute to this growth, advancing life-changing solutions used across the world while creating even more high-wage career opportunities that allow Hoosiers to thrive.”
Cutting-Edge Facility Development
The new facility will encompass approximately 450,000 square feet and is set to be built at the Anson Industrial Park in Boone County. This state-of-the-art site will enable RayzeBio to enhance its production capacity for next-generation radiopharmaceutical therapies (RPTs). These therapies utilize radioisotopes to precisely target cancer cells, minimizing damage to surrounding healthy tissues and potentially improving patient outcomes.
Enhancing Existing Operations
Construction of the new facility is anticipated to commence this year and will complement RayzeBio’s current 77,000-square-foot facility on the northeast side of Indianapolis. This existing site is equipped to meet both clinical and commercial supply needs throughout the United States and globally. The company aims to recruit for advanced manufacturing roles across both locations, with average annual wages projected to exceed $130,000.
Strategic Importance of Indiana
Ben Hickey, president of RayzeBio, highlighted the strategic importance of Indiana in their overarching plan to develop the infrastructure necessary for advancing radiopharmaceutical therapies. He remarked, “This investment expands our manufacturing capabilities, creates high-quality jobs, and strengthens our ability to deliver innovation for patients. We’re proud to grow our presence in Indiana and contribute to the state’s emergence as a leading hub for life sciences manufacturing.”
RayzeBio’s Mission and Future Plans
Founded in 2020 and acquired by Bristol Myers Squibb in 2024, RayzeBio is dedicated to improving cancer treatments and transforming lives. The company focuses on actinium-based RPTs and is developing a pipeline of investigational drugs aimed at treating various solid tumors, including gastroenteropancreatic neuroendocrine tumors (GEP-NET), liver cancer, and prostate cancer.
A Vision for Life Sciences
RayzeBio’s expansion is aligned with Indiana’s vision to solidify its position as the Radiopharmaceutical Capital of the World. This growth aligns with the Governor’s life sciences initiative, which aims to leverage a $1 billion investment over ten years to make Indiana a premier destination for human, animal, and plant health. The state is committed to fostering innovation and attracting new investments to further develop the BioHeartland.
In conclusion, RayzeBio’s $173 million investment marks a significant milestone for Indiana’s life sciences sector. With the creation of 100 new jobs and the construction of a state-of-the-art facility, Indiana is poised to enhance its reputation as a leader in radiopharmaceutical manufacturing. This initiative not only promises economic growth but also signifies a commitment to advancing healthcare solutions for cancer patients.
- RayzeBio’s $173 million investment enhances Indiana’s life sciences capacity.
- The new facility will create 100 high-wage jobs by 2029.
- Indiana remains committed to becoming the Radiopharmaceutical Capital of the World.
- The investment supports the Governor’s $1 billion initiative in life sciences.
- RayzeBio focuses on innovative cancer treatments through advanced manufacturing.
Read more → www.wbiw.com